Soligenix, Inc. (SNGX) Prices $4.75 Million Public Offering

Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.40 per share, will be exercisable immediately and will expire five years from the issuance date.

The closing of the offering is expected to occur on or about April 22, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund the Company's research and development and commercialization activities, and for general corporate and working capital purposes.

A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

A registration statement on Form S-1 (File No. 333-276511) relating to the sale of these securities was declared effective by the Securities and Exchange Commission (the "SEC") on April 15, 2024. This offering is being made only by means of a prospectus. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Electronic copies of the prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• RenovoRx regains Nasdaq minimum bid price compliance
• WISeKey names Alexander Hirsch as group chief marketing officer